Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.69 |
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | GAA | P10253 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | GFER | P55789 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GRK2 | P25098 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067333 | 1.00 | ALDH1A1 (0.71) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL4413307 | 0.87 | GAA (0.69) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL13345208 | 0.87 | GAA (0.69) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL3273659 | 0.87 | GAA (0.69) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL21812480 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL21812481 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL8230499 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL6681732 | 0.81 | RAB9A (0.63) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL6681734 | 0.81 | RAB9A (0.63) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL28874997 | 0.80 | MEN1 (0.57) | ALDH1A1KDM4EKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| WO-2011121629-A1 | INDOLIC DERIVATIVES AND USE THEREOF IN MEDICAL FIELD | UNIVERSITA' DEGLI STUDI DL ROMA "LA SAPIENZA" (IT) | 2011-10-06 | — | — | WO | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| EP-1915374-A2 | 2-INDOLYL IMIDAZO[4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | GeneSense Technologies Inc. (CA) | 2008-04-30 | — | — | EP | disclosed |
| WO-2006126177-A2 | 2-INDOLYL IMIDAZO[4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | GENESENSE TECHNOLOGIES INC. (CA) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | FLI1, IKZF3, IKZF2 | ALDH1A1 474/4885KDM4E 155/4885KMT2A 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.